Incyte Corporation - Common Stock (NQ:INCY)

115.30 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

29 30 Next >

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 06, 2024

From Incyte

Via Business Wire

Incyte Announces Updated Presentation Time for Upcoming Investor Conference

November 26, 2024

From Incyte

Via Business Wire

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting

November 25, 2024

From Incyte

Via Business Wire

Target, Alibaba And Temu Parent PDD Are Among Top 10 Large-Cap Losers Last Week (Nov 18-Nov 22): Are The Others In Your Portfolio? ↗

November 24, 2024

Large-cap stocks had a rough week, including Target, PDD Holdings, ZTO Express, Tenet Healthcare, Ulta Beauty, Intuit, Nokia, Alibaba, Santander, and Incyte.

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Incyte ↗

November 14, 2024

Via Benzinga

Incyte Breaks Out To 17-Month High As Jakafi Demand Surges ↗

October 29, 2024

Sales of the company's two key products, Jakafi and Opzelura, jumped.

Via Investor's Business Daily

Stock Market Rallies After Key Test; Nvidia, Target, Google, Bitcoin In Focus: Weekly Review ↗

November 22, 2024

Many leaders flashed buy signals. Bitcoin raced toward $100,000.

Via Investor's Business Daily

Despite its impressive fundamentals, NASDAQ:INCY remains undervalued. ↗

November 20, 2024

INCYTE CORP (NASDAQ:INCY) is probably undervalued for the fundamentals it is displaying.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 19, 2024

Via Benzinga

Nasdaq Reverses Losses Amid Nvidia Fanfare ↗

November 19, 2024

Stocks are attempting to walk back this morning's losses tied to escalating tensions between Russia and Ukraine.

Via Talk Markets

Gold Moves Higher; Medtronic Posts Upbeat Results ↗

November 19, 2024

Via Benzinga

Stocks Move Higher, Walmart Hits Record High, Natural Gas Reaches 5-Month Peak: What's Driving Markets Tuesday? ↗

November 19, 2024

Wall Street managed to recover from a red start caused by heightened geopolitical tensions stemming from the ongoing Russia-Ukraine conflict.

Via Benzinga

Topics Energy

What's Going On With Incyte Shares Tuesday? ↗

November 19, 2024

Incyte stock is trading lower on Tuesday after the company announced that data from its Phase 2 study does not support further development.

Via Benzinga

Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

November 19, 2024

Via Benzinga

Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges ↗

November 19, 2024

Incyte pauses MRGPRX2 study enrollment due to toxicology concerns, with analysts calling the update disappointing amid pipeline reevaluations.

Via Benzinga

Nasdaq Gains 100 Points; Lowe's Earnings Beat Views ↗

November 19, 2024

Via Benzinga

Topics Earnings

Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered. ↗

November 19, 2024

The company is discontinuing development of one drug and pausing enrollment in the study of another.

Via Investor's Business Daily

Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket ↗

November 19, 2024

Via Benzinga

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

November 18, 2024

From Incyte

Via Business Wire

Incyte to Present at Upcoming Investor Conference

November 14, 2024

From Incyte

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 13, 2024

Via Benzinga

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 07, 2024

From Incyte

Via Business Wire

Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock ↗

October 30, 2024

Incyte reports strong Q3 earnings, driven by Jakafi growth, prompting BofA upgrade with a new price target of $90.

Via Benzinga

Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review ↗

November 01, 2024

The major indexes declined, but haven't fallen apart.

Via Investor's Business Daily

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights ↗

October 30, 2024

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.

Via Benzinga

This Alphabet Analyst Turns Bullish; Here Are Top 5 Downgrades For Wednesday ↗

October 30, 2024

Via Benzinga

Incyte to Present at Upcoming Investor Conferences

October 30, 2024

From Incyte

Via Business Wire

Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura ↗

October 29, 2024

Incyte reports Q3 revenue of $1.04B, driven by strong Jakafi and Opzelura sales, and raises 2024 guidance amid competitive market challenges.

Via Benzinga

Corning Posts Upbeat Q3 Earnings, Joins Opera, Inari Medical, Incyte And Other Big Stocks Moving Higher On Tuesday ↗

October 29, 2024

Via Benzinga

Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

October 29, 2024

From Incyte

Via Business Wire

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.